aTyr Pharma

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

4 Stocks You Need To Buy Now for Consistent Profits—Here’s Why Analysts Love Them

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ATYR

ENGN

ESLA

SHLS

This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Analysts Pick 4 Stocks Poised for Growth, Including Tech Giants Microsoft And Meta

NNOX

TOST

TTAN

This Toast Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Penny,Stock,Investments,Taking,Off,Concept

Long Ideas

Penny Stocks

Insider Trades

Super League Enterprise And 2 Other Stocks Under $2 Insiders Are Buying

aTyr Pharma Inc

Press Releases

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

Biotech

Health Care

General

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine

Earnings

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

aTyr Pharma to Participate in April Investor Conferences

aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025

Abeona Therapeutics

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Astria Therapeutics

Aura Biosciences

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Cidara Therapeutics

Checkpoint Therapeutics, Inc. - Common Stock

Checkpoint Therapeutics

Design Therapeutics

Emergent BioSolutions

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Heron Therapeutics

ITeos Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Monopar Therapeutics

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Rezolute

Solid Biosciences

Acelyrin

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

2seventy bio

XOMA Royalty

HC Wainwright & Co.

Leerink Partners

Wells Fargo

Jefferies

RBC Capital

Comments

aTyr Pharma

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell